
IBM Stock: Stable Dividend or Stagnant Investment?
The AI race has heated up significantly but returns on…
Trailing 12 Months | Fiscal Quarters | |||||
---|---|---|---|---|---|---|
Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
Income Statement | ||||||
Revenue | $2.7M | $2.1M | $37.2M | $539K | $15.1M | |
Gross Profit | $2M | $1.4M | $31M | $368K | $13M | |
Operating Income | -$33.9M | -$38.2M | -$12.4M | -$11.3M | $3M | |
EBITDA | -$33.7M | -$37.8M | -$15.2M | -$3M | $10.5M | |
Diluted EPS | -$4.14 | -$2.82 | -$0.98 | -$0.33 | -$0.11 |
Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
---|---|---|---|---|---|---|
Balance Sheet | ||||||
Current Assets | $32.3M | $31.2M | $16.2M | $37.2M | $73.8M | |
Total Assets | $34.6M | $33.1M | $17.9M | $38.6M | $76.6M | |
Current Liabilities | $10M | $6M | $14.7M | $16.4M | $6.1M | |
Total Liabilities | $12.6M | $21.2M | $23.7M | $22.8M | $7.8M | |
Total Equity | $22.1M | $12M | -$5.9M | $15.8M | $68.7M | |
Total Debt | $2M | $15.6M | $15.7M | $10.2M | -- |
Trailing 12 Months | Fiscal Quarters | |||||
---|---|---|---|---|---|---|
Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
Cash Flow Statement | ||||||
Cash Flow Operations | -$25M | -$31.3M | -$18.7M | -$8.2M | -$1M | |
Cash From Investing | -$209K | -$19.7M | -$981K | -$19.7M | -$15.2M | |
Cash From Financing | $10.1M | $51.8M | $39.4M | $1K | $40.4M | |
Free Cash Flow | -$25.2M | -$31.3M | -$19.2M | -$8.2M | -$1.2M |
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
In the current month, DCTH has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The DCTH average analyst price target in the past 3 months is $22.50.
According to analysts, the consensus estimate is that Delcath Systems share price will rise to $22.50 per share over the next 12 months.
Analysts are divided on their view about Delcath Systems share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Delcath Systems is a Sell and believe this share price will drop from its current level to $21.00.
The price target for Delcath Systems over the next 1-year time period is forecast to be $22.50 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
According to Wall Street analysts, the consensus rating for Delcath Systems is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
You can purchase shares of Delcath Systems via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Delcath Systems shares.
Delcath Systems was last trading at $11.82 per share. This represents the most recent stock quote for Delcath Systems. Yesterday, Delcath Systems closed at $12.98 per share.
In order to purchase Delcath Systems stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Signup to receive the latest stock alerts
The AI race has heated up significantly but returns on…
Trimble (NASDAQ:TRMB) is a hardware and software tech company that…
It seems like right now is a good time to…
Market Cap: $3.6T
P/E Ratio: 39x
Market Cap: $2.8T
P/E Ratio: 32x
Market Cap: $2.6T
P/E Ratio: 36x
Willdan Group [WLDN] is down 3.66% over the past day.
Pro-Dex [PDEX] is up 10.33% over the past day.
Samsara [IOT] is down 3.68% over the past day.